TEL AVIV, Israel, November 30, 2017 /PRNewswire/ --
EarlySense, the market leader in contact-free continuous
EarlySense had a Composite Annual Growth Rate (CAGR) of 111% in revenue from 2013-2016, resulting from increased global adoption of its analytics and sensing solutions for hospitals, post-acute care facilities and the consumer health market. The achievement highlights the success of EarlySense's InSight™ platform for medical facilities, and comes on the heels of two new consumer products, Live™ for the aging population and Percept™ for couples who are trying to conceive.
"EarlySense's inclusion in the Technology Fast 50 for the second consecutive year shows a deep understanding of the global health and technology market," said Shally Tshuva, Technology, Media & Telecommunications Industry Leader at Deloitte Israel. "EarlySense is a prime example of a business success story. The strong growth rate indicates the need for EarlySense's advanced medical and consumer health solutions, and the benefits they provide for patients, medical teams and families."
EarlySense's technology uses a wireless sensor placed under a bed mattress, or within a chair, to track real time health data, including heart rate, breathing rate, sleep cycles, stress levels and movement. The FDA-cleared medical solution assists health teams with early detection of patient deterioration to prevent adverse events and improve health outcomes. The consumer solutions leverage the same hospital-proven technology in an easy-to-use interface, enabling users to effectively monitor their wellbeing and make better health choices.
"Being one of the 50 fastest growing technology companies is an exceptional achievement, and the culmination of years of continued clinical research, innovation, adaptation and hard work by our incredible global team," said Avner Halperin, Co-founder and CEO of EarlySense. "The benefits of our technology are clear - we help keep patients safe, empower medical teams, and help people live better lives. EarlySense solutions are rapidly being adopted worldwide -across the healthcare continuum- and we look forward to another strong year of growth."
EarlySense® provides contact-free, continuous monitoring solutions for the medical and consumer digital health markets. EarlySense's integrated sensor utilizes Artificial Intelligence (AI) and big data analytics to provide actionable health insights and improve clinical outcomes.
Used worldwide in hospitals, rehab and skilled nursing facilities, EarlySense assists clinicians in early detection of patient deterioration, helping to prevent adverse events, including code blues which are a result of cardiac or respiratory arrest, preventable ICU transfers, patient falls and pressure ulcers.
EarlySense offers clinically-proven technology to consumers with EarlySense® Live™ and Percept™. EarlySense® Live™ is the first at-home consumer health monitor powered by EarlySense's medically-proven sensor and AI analytics. Live is particularly useful for tracking the health and sleep of the aging population and children, to help facilitate better health choices. EarlySense® Percept™ is the first clinically-proven contactless monitor for fertility and period tracking. It accurately tracks internal body signals and assists couples who are trying to conceive.
EarlySense has partnered with leading global technology companies including Samsung, Welch Allyn, iFit and Beurer. The company is based in Ramat Gan, Israel and Waltham, MA. For more information, visit www.earlysense.com, www.earlysense.com/live and www.earlysense.com/percept.
Follow EarlySense on LinkedIn, Twitter and Facebook, EarlySense Live on Facebook and Twitter and Percept at Facebook, Instagram, and Twitter.
EarlySense Contact: Hila Peleg +972-54-527-3117 email@example.com
Media Contact: Ellie Hanson FinnPartners +1-929-222-8006 firstname.lastname@example.org
Subscribe to our Free Newsletters!
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...
Fosnetupitant and Palonosetron (a fixed antiemetic combination) injection was approved by FDA in ...View All